There is a rapidly-growing body of robust literature supporting the implementation of PGx into clinical practice. The Clinical Pharmacogenetics Implementation Consortium (CPIC) produces guidelines that are peer-reviewed, regularly updated, and freely available (see link below) to guide drug therapy with certain gene-drug pairs in the presence of certain genetic variants. Many of these gene-drug pairs and genetic variants are well-studied, clinically significant and actionable in everyday medical practice.
Dr. Jennifer Marquez is trained to analyze and interpret the data in the 20-40 page genetic reports that result from PGx testing, as well as the related gene-drug pair guidelines and complexities of drug-gene, drug-drug, and drug-drug-gene interactions. Drug-drug-gene interactions can be very complex, and sometimes adding a second drug that interacts with a certain gene will cause something called phenoconversion to occur. This is a phenomenon that converts genotypic extensive metabolizers into phenotypic poor metabolizers of drugs.
A few links and references are posted here for your convenience and review.
